Uroselectivity in male dogs of silodosin (KMD‐3213), a novel drug for the obstructive component of benign prostatic hyperplasia

Abstract

Our results clearly demonstrate that silodosin is a potent and highly selective alpha(1A)-AR antagonist. A selective alpha(1A)-AR antagonist such as silodosin may have good potential as a less-hypotensive drug for the treatment of urinary dysfunction in benign prostatic hyperplasia patients.